Filik Mustafa, Kir Kemal Metin, Aksel Bülent, Soyda Çiğdem, Özkan Elgin, Küçük Özlem Nuriye, İbiş Erkan, Akgül Hikmet
Prof. Dr. A. İlhan Özdemir State Hospital, Clinic of Nuclear Medicine, Giresun, Turkey. E-mail:
Mol Imaging Radionucl Ther. 2015 Feb 5;24(1):15-20. doi: 10.4274/mirt.26349.
The aim of this study is to explore the role of 18F-FDG PET/CT in the primary staging of gastric cancer in the comparison of ceCT as routine staging method and evaluate influencing parameters of 18F-FDG uptake.
Thirty-one patients (mean age: 58.9±12.6) who underwent 18F-FDG PET/CT for primary staging of gastric cancer between June 2011 and June 2012 were included to the study. 18F-FDG PET/CT findings were compared with pathological reports in patients who underwent surgery following PET/CT. 18F-FDG PET/CT findings of primary lesions, lymph nodes and adjacent organs were compared with ceCT findings and pathological reports. Since 6 patients were accepted as inoperable according to 18F-FDG PET/CT and/or ceCT and/or laparotomy and/or laparoscopy findings, pathological confirmation could not be possible.
In the postoperative TNM staging of patients, while 1 (4%), 1 (4%), 4 (16%), 2 (8%), 12 (48%) and 5 (20%) patients were staged as T0, Tis, T1, T2, T3 and T4, respectively, 8 (32%), 6 (24%), 6 (24%) and 5 (20%) patients were N0, N1, N2 and N3 respectively. 18F-FDG PET/CT was totally normal in 2 patients. While primary tumors were FDG avid in 27 patients, in 17 and 6 patients FDG uptake was observed in perigastric lymph nodes and distant organs, respectively. Mean SUVmax of FDG avid tumors was calculated as 13.49±9.29 (3.00-44.60). However, SUVmax of lymph nodes was computed as 9.28±6.92 (2.80-29.10). According to sub-analysis of histopathological subtypes of primary tumors, SUVmax of adenocarsinomas was calculated as 15.16 (3.00-44.60), of signet ring cells as 9.90 (5.50-17.70), of adenocarcinomas with signet ring cell component as 11.27 (6.20-13.90) (p=0.721). In the comparison with histopathological examination while ceCT was TP, TN, FN in 23, 1 and 1 patients, 18F-FDG PET/CT was TP, FP, FN in 20, 1 and 4 patients, respectively. Sensitivity, specificity, accuracy, PPD and NPV of ceCT in the detection of lymph node metastasis was calculated as 83.3%, 75%, 80%, 87.5% and 66.6%, respectively. These parameters for 18F-FDG PET/CT were 64.7%, 100%, 76%, 100% and 57.1%.
Despite lower sensitivity than ceCT, diagnostic power of 18F-FDG PET/CT in the preoperative staging of gastric cancer is acceptable. Because of its high PPV, it might be beneficial in the evaluation of patients with suspected lymph nodes. The role of 18F-FDG PET/CT seems to be limited in the early stage and signet ring cell carcinomas due to lower 18F-FDG uptake.
本研究旨在探讨18F-FDG PET/CT在胃癌初始分期中的作用,与作为常规分期方法的增强CT(ceCT)进行比较,并评估18F-FDG摄取的影响参数。
纳入2011年6月至2012年6月期间因胃癌初始分期接受18F-FDG PET/CT检查的31例患者(平均年龄:58.9±12.6岁)。将18F-FDG PET/CT检查结果与PET/CT检查后接受手术的患者的病理报告进行比较。将原发灶、淋巴结及邻近器官的18F-FDG PET/CT检查结果与ceCT检查结果及病理报告进行比较。由于6例患者根据18F-FDG PET/CT和/或ceCT和/或剖腹探查和/或腹腔镜检查结果被判定为不可手术,因此无法获得病理确诊。
在患者术后TNM分期中,分别有1例(4%)、1例(4%)、4例(16%)、2例(8%)、12例(48%)和5例(20%)患者分期为T0、Tis、T1、T2、T3和T4,分别有8例(32%)、6例(24%)、6例(24%)和5例(20%)患者N0、N1、N2和N3。2例患者的18F-FDG PET/CT完全正常。27例患者的原发肿瘤呈FDG摄取阳性,17例和6例患者分别在胃周淋巴结和远处器官观察到FDG摄取。FDG摄取阳性肿瘤的平均SUVmax计算为13.49±9.29(3.00 - 44.60)。然而,淋巴结的SUVmax计算为9.28±6.92(2.80 - 29.10)。根据原发肿瘤组织病理学亚型的亚组分析,腺癌的SUVmax计算为15.16(3.00 - 44.60),印戒细胞癌为9.90(5.50 - 17.70),伴有印戒细胞成分的腺癌为11.27(6.20 - 13.90)(p = 0.721)。与组织病理学检查相比,ceCT在23例、1例和1例患者中分别为真阳性(TP)、真阴性(TN)、假阴性(FN),18F-FDG PET/CT在20例、1例和4例患者中分别为TP、假阳性(FP)、FN。ceCT检测淋巴结转移的敏感性、特异性、准确性、阳性预测值(PPD)和阴性预测值(NPV)分别计算为83.3%、75%、80%、87.5%和66.6%。18F-FDG PET/CT的这些参数分别为64.7%、100%、76%、100%和5